Q1 2025 Stevanato Group SpA Earnings Call Transcript
Key Points
- Stevanato Group SpA (STVN) reported a 9% revenue growth in the first quarter of 2025, exceeding expectations.
- The Biopharmaceutical and Diagnostic Solutions (BDS) segment showed strong operational delivery, with an 11% revenue increase.
- High-value solutions accounted for 43% of total revenue, driven by strong demand for high-value syringes.
- Gross profit margin improved by 80 basis points to 27.2%, supported by capacity expansions at Latina and Fishers facilities.
- The company is on track with its capital investment projects, with ongoing installations and scaling of commercial syringe production at Fishers and Latina.
- The Engineering segment experienced a 4% revenue decline, primarily due to lower sales from pharmaceutical visual inspection and glass conversion lines.
- Gross profit margins in the Engineering segment were below expectations, impacted by the legacy projects in Denmark.
- Tariffs are expected to have a $4.5 million impact on operating profit, affecting diluted earnings per share by approximately $0.01.
- The company anticipates a stronger second half of fiscal 2025, indicating potential challenges in maintaining momentum in the first half.
- Free cash flow guidance remains negative for 2025, with expectations of EUR40 million to EUR60 million negative free cash flow for the year.
Good afternoon. This is the Chorus call conference operator. Welcome, and thank you for joining the Stevanato Group first quarter 2025 results conference call. (Operator Instructions)
At this time, I would like to turn the conference over to Ms. Lisa Miles, Senior Vice President, Investor Relations. Please go ahead, madam.
Good morning, and thank you for joining us. With me today are Franco Stevanato, Chief Executive Officer; and Marco Dal Lago, Chief Financial Officer. A presentation to accompany today's results is available on the Investor Relations page of our website under the Financial Results tab.
As a reminder, some statements being made today are forward-looking and based on current expectations. Actual results may differ materially due to risks outlined in Item 3D, Risk Factors of our most recent annual report on Form 20-F filed with the SEC. Please review the safe harbor statement included at the beginning of today's presentation and in our press release.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
